(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2025 (25.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/199438 A1

(51) International Patent Classification:
A61K 31/395 (2006.01) *A61K 31/437* (2006.01)
A61K 31/4353 (2006.01) *A61K 31/33* (2006.01)

(21) International Application Number:
PCT/US2025/020911

(22) International Filing Date:
21 March 2025 (21.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/568,828	22 March 2024 (22.03.2024)	US
63/685,900	22 August 2024 (22.08.2024)	US
63/766,726	04 March 2025 (04.03.2025)	US

(71) Applicant: **BLOSSOMHILL THERAPEUTICS, INC.** [US/US]; 3525 John Hopkins Court, Suite 100, San Diego, California 92121 (US).

(72) Inventors: **CUI, Jingrong Jean**; 3525 John Hopkins Court, Suite 100, San Diego, California 92121 (US). **RUI, Eugene Yuanjin**; 3525 John Hopkins Court, Suite 100, San Diego, California 92121 (US). **ROGERS, Evan W.**; 3525 John Hopkins Court, Suite 100, San Diego, California 92121 (US). **LIPTAK, Vincent P.**; 3525 John Hopkins Court, Suite 100, San Diego, California 92121 (US).

(74) Agent: **LEWALLEN, Daniel M.**; Barnes & Thornburg LLP, 11 South Meridian Street, Indianapolis, Indiana 46204 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

WO 2025/199438 A1

(54) Title: 7-AZAINDAZOLE MACROCYCLES AND THEIR USE

(57) Abstract: The present disclosure relates to ether linked macrocyclic compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat disease, such as cancer.